201 related articles for article (PubMed ID: 12075825)
1. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system.
Wu D; Song BW; Vinters HV; Pardridge WM
J Drug Target; 2002 May; 10(3):239-45. PubMed ID: 12075825
[TBL] [Abstract][Full Text] [Related]
2. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector.
Song BW; Vinters HV; Wu D; Pardridge WM
J Pharmacol Exp Ther; 2002 May; 301(2):605-10. PubMed ID: 11961063
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
4. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Saito Y; Buciak J; Yang J; Pardridge WM
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757
[TBL] [Abstract][Full Text] [Related]
5. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.
Pardridge WM; Wu D; Sakane T
Pharm Res; 1998 Apr; 15(4):576-82. PubMed ID: 9587954
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu D; Pardridge WM
J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
[TBL] [Abstract][Full Text] [Related]
7. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.
Pardridge WM; Kang YS; Buciak JL
Pharm Res; 1994 May; 11(5):738-46. PubMed ID: 8058646
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
9. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.
Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622
[TBL] [Abstract][Full Text] [Related]
10. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
11. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
12. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
[TBL] [Abstract][Full Text] [Related]
13. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and brain uptake of lactoferrin in rats.
Ji B; Maeda J; Higuchi M; Inoue K; Akita H; Harashima H; Suhara T
Life Sci; 2006 Jan; 78(8):851-5. PubMed ID: 16165165
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody.
Wu D; Pardridge WM
Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674
[TBL] [Abstract][Full Text] [Related]
16. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells.
Kang YS; Voigt K; Bickel U
J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668
[TBL] [Abstract][Full Text] [Related]
17. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate.
Li XB; Liao GS; Shu YY; Tang SX
J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183
[TBL] [Abstract][Full Text] [Related]
18. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition.
Edelman ER; Nugent MA; Karnovsky MJ
Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1513-7. PubMed ID: 8434012
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
Zhang Y; Pardridge WM
Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor.
Deguchi Y; Naito T; Yuge T; Furukawa A; Yamada S; Pardridge WM; Kimura R
Pharm Res; 2000 Jan; 17(1):63-9. PubMed ID: 10714610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
